Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen/KK’s Atopic Dermatitis Deal Shows OX40’s Allure, But Market Still Tough

Amgen will pay $400m upfront and up to $850m in milestones

Executive Summary

Amgen said Phase II data are planned for the EADV 2021 meeting, but KHK4083 will need a strong showing.

You may also be interested in...



Amgen Wins World-First Lumakras Approval, Faces Challenge Of COVID-Era Launch

Commercial EVP Murdo Gordon said launching sotorasib during the pandemic is a tougher challenge than encouraging doctors to screen lung cancer patients for KRAS G12C mutations and raising patient awareness.

Oral Atopic Dermatitis Market Crowded, But Arena Sees Room

The company showed improvement on an endpoint used in several Phase III studies of JAK inhibitors, but with a potentially better safety profile.

Sanofi Hits M&A Trail Again To Buy UK's KyMab

Another UK biotech has been swallowed up by a big pharma with Sanofi acquiring the Cambridge-based firm in a deal that could be worth almost $1.5bn.

Related Content

Related Companies

UsernamePublicRestriction

Register

SC144453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel